A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Phase 1 Terminated 12 enrolled Elan Pharmaceuticals

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety and tolerability of ELND002 in patients with multiple sclerosis (MS) after participation in study MS103.

Timeline

Start: 2010-12
Primary completion: 2012-12
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ELND002	Unknown	—	Subcutaneous

A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Summary

Timeline

Drugs

Indications